Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction.

摘要: Eur J Clin Invest 2011; 41 (11): 1210–1219 Abstract Background  In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods  Blood sampling was performed before PPCI. Consecutive (n = 24) or without evidence angiographic after PPCI were enrolled. Angiographic defined as Thrombolysis Myocardial Infarction (TIMI) flow ≤ 2 TIMI flow = 3 but blush grade < 2. also assessed electrocardiographic (ECG) ≤ 50% resolution maximal ST elevation 60 min PPCI. Results  Baseline characteristics did not correlate significantly concentrations. contrast, both ECG correlated lower levels at univariate analysis [median (interquartile): 4·2 (0·6–9·5) vs. 12·2 (5·2–20·3) mIU mL−1, P = 0·001, 4·0 (0·6–7·1) 9·3 (1·0–12·6) P = 0·01, respectively]. At multivariable analysis, decreasing tertiles left anterior descending infarct-related artery only factors that predicted (P = 0·017 P = 0·02 for EPO; P   0·05 artery, respectively). Conclusions  an independent, graded, inverse relation following animal be protective. humans, may contribute offset mechanisms responsible no-reflow.